December began with what looks like an end-of-year venture capital dealmaking rush, including an $80m Series C round to fund Naurex's drug candidates for depression and central nervous system (CNS) disorders plus four other sizeable US biotechnology deals.
Biotech venture capital investment in 2014 already is poised to outpace 2013's total and VC investors in the US came back from Thanksgiving vacation with funding announcements that could ensure this year ends ahead of last year (scripintelligence.com, 26 October 2014)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?